Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ferring Japan Starts Own Marketing Of Fertility Drug

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Ferring Pharma, a Japanese subsidiary of the Swiss drug maker Ferring Pharmaceuticals, announced July 7 that it will begin its own marketing efforts beginning July 28. Its first product is the fertility drug human menopausal gonadotropin (hMG) injection 75IU. Ferring Pharma has been marketing an ulcerative colitis drug and human growth hormone products through partners, and the company's annual sales are ¥25 billion. With the start of its own marketing, Ferring estimates sales to reach ¥30 billion by 2017, accounting for 10 percent of worldwide sales. The company will focus on infertility and urology as it looks to further widen its product pipeline. Ferring Pharma also started jointly marketing enuresis drug desmopressin with Kyowa Hakko in July. (Click here for more - Japanese language

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts